Summary
The provided content includes label excerpts, but the AI-generated response to be evaluated is not actually the excerpted label claims; instead it contains an additional meta-audit text with unverifiable claims and an internal audit narrative that cannot be checked against the FDA label due to missing direct mapping to the exact statements in the evaluated response.
Category Scores
Accurate Statements
Premature discontinuation of XARELTO increases thrombotic risk
Boxed Warning A and Section 5.1 excerpts provided in the prompt
Spinal/epidural hematoma can occur in patients treated with XARELTO undergoing neuraxial anesthesia or spinal puncture
Boxed Warning B, Section 5.3, and Section 17 excerpts provided in the prompt
Unsupported Statements
The evaluation references 'Boxed Warning A' and 'Section 5.1' without providing the actual FDA label section numbers/text; therefore 'cannot be fully verified.'
The prompt itself provides the boxed warning text and Section 5.1/5.3/17 excerpts; thus the 'cannot be fully verified' conclusion is unsupported relative to the supplied excerpts.
Whether contraindications/other major warnings/dosing/pregnancy or pediatric safety omissions can be determined cannot be assessed from the provided input.
The user provided label excerpts specifically covering boxed warning topics; however the response’s omission assessment is not auditable here because the response being evaluated did not actually present an FDA-label-structured drug monograph beyond the two claims. This portion is not demonstrably supported or necessary for the specific claim evaluation.
Contradictions
Low
AI Statement
The response indicates the claims cannot be fully verified because boxed warning citations/text were not provided.
Label Reference
Contradicted by the prompt-provided FDA label excerpts for Boxed Warning A/B and Sections 5.1, 5.3, 17.
Important Omissions
No explicit discussion of risk-reduction monitoring instructions (e.g., frequent neurological monitoring, patient symptom reporting, urgent treatment guidance) as part of claim-level justification.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the two core warnings appear aligned with the provided label excerpts, the response includes unsupported statements about inability to verify label support, which could undermine audit reliability.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The response asserts label claims cannot be fully verified despite the prompt providing the relevant boxed warning and section text, reducing audit reliability.
Suggested Improvement
When evaluating against supplied excerpts, cite and justify directly from the provided label text for each claim (including monitoring/counseling language) and avoid stating 'cannot be verified' if the excerpt is already present.